Hospital
The Charlotte-Mecklenburg Hospital Authority
The Charlotte-Mecklenburg Hospital Authority was paid $38.15M by Medicaid between Jan 2018 and Dec 2024, across 147 billing codes. Its largest line is 99283, emergency room visit (moderate) — 33% of everything it billed.
33Billing provider infoTHE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY
MONROE, NC 28112
MONROE, NC 28112
33aNPI1396790325assigned 05/25/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$38.15M
24GClaims539,295
24DCodes billed147
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#15 of 92
Median peer was paid$11.47M
This provider vs. median3.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DEFURIO, ANTHONY controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 89,138 | $4.52M | |
| 2019 | 84,152 | $4.36M | |
| 2020 | 56,055 | $2.43M | |
| 2021 | 61,113 | $4.36M | |
| 2022 | 78,381 | $6.60M | |
| 2023 | 85,546 | $8.15M | |
| 2024incomplete | 84,910 | $7.73M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 33% | 60,153 | 56,556 | $12.56M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 27% | 53,651 | 49,517 | $10.42M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.3% | 20,007 | 18,364 | $3.53M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 4.8% | 12,754 | 11,998 | $1.85M |
| J3490 | Unclassified drugs | 4.6% | 45,557 | 23,615 | $1.75M |
| 80053 | Comprehensive metabolic panel | 2.4% | 14,621 | 12,741 | $909K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 1.8% | 25,792 | 10,701 | $696K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.7% | 19,672 | 17,667 | $637K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 7,533 | 7,206 | $603K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 15,988 | 14,499 | $401K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.0% | 18,766 | 15,537 | $394K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,832 | 4,133 | $358K |
135 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 21,771 | $309K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,079 | $245K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,531 | $229K |
| 80047 | <1% | 8,950 | $226K | |
| 71045 | Radiologic examination, chest; single view | <1% | 11,396 | $217K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,518 | $200K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 27,872 | $186K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,291 | $183K |
| 87070 | <1% | 1,013 | $146K | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 1,054 | $141K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,770 | $135K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,690 | $127K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 587 | $113K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,270 | $104K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,242 | $101K |
| 82962 | <1% | 1,755 | $94K | |
| 85027 | <1% | 17,115 | $90K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,933 | $86K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,191 | $85K |
| G0378 | Hospital observation service, per hour | <1% | 1,576 | $64K |
| 81001 | <1% | 13,034 | $57K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,564 | $55K |
| 81025 | <1% | 5,447 | $53K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 251 | $50K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,154 | $49K |
| 87081 | <1% | 568 | $43K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 688 | $41K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,082 | $39K |
| 84484 | <1% | 7,511 | $35K | |
| 81003 | <1% | 2,364 | $31K | |
| 87210 | <1% | 925 | $28K | |
| 64483 | <1% | 105 | $27K | |
| 84702 | <1% | 545 | $25K | |
| 81002 | <1% | 2,266 | $21K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 893 | $21K |
| 0002A | <1% | 366 | $20K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 782 | $19K |
| 97597 | <1% | 769 | $18K | |
| 0001A | <1% | 346 | $18K | |
| 83690 | <1% | 5,514 | $17K | |
| 87430 | <1% | 1,149 | $16K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,539 | $15K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 77 | $15K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,025 | $14K |
| 87486 | <1% | 56 | $14K | |
| 73130 | <1% | 105 | $13K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,366 | $13K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,482 | $12K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 236 | $12K |
| 73630 | <1% | 168 | $11K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,431 | $11K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 116 | $9K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,758 | $8K |
| 82728 | <1% | 714 | $8K | |
| 84466 | <1% | 702 | $7K | |
| Q3014 | Telehealth originating site facility fee | <1% | 591 | $6K |
| 80076 | <1% | 1,536 | $6K | |
| 82607 | <1% | 486 | $6K | |
| 73110 | <1% | 26 | $5K | |
| 73560 | <1% | 79 | $5K | |
| A9270 | Non-covered item or service | <1% | 9,527 | $5K |
| 73610 | <1% | 43 | $4K | |
| 59025 | Fetal non-stress test | <1% | 46 | $4K |
| 80061 | Lipid panel | <1% | 471 | $4K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 311 | $4K |
| 83540 | <1% | 706 | $4K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 53 | $4K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 568 | $3K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 173 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 332 | $3K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 12 | $3K |
| 82803 | <1% | 769 | $3K | |
| 20610 | <1% | 32 | $3K | |
| 83880 | <1% | 800 | $3K | |
| 83735 | <1% | 1,627 | $3K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 39 | $3K |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 1,371 | $2K |
| 82248 | <1% | 1,210 | $2K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 12 | $2K |
| 87077 | <1% | 16 | $2K | |
| 82075 | <1% | 461 | $2K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 14 | $2K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 17 | $2K |
| 77336 | <1% | 45 | $2K | |
| 83605 | <1% | 1,537 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 97 | $2K |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 911 | $1K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 56 | $1K |
| 93975 | <1% | 220 | $1K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 577 | $1K |
| 85014 | <1% | 751 | $948.22 | |
| 20553 | <1% | 14 | $945.77 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 88 | $808.90 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,337 | $806.45 |
| 74018 | <1% | 12 | $801.47 | |
| 73030 | <1% | 18 | $730.09 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 110 | $625.45 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 179 | $331.57 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 169 | $285.39 |
| J2704 | Injection, propofol, 10 mg | <1% | 114 | $243.01 |
| 96127 | <1% | 191 | $240.97 | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 12 | $227.22 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 87 | $202.71 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 79 | $202.05 |
| 85610 | <1% | 44 | $123.04 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 72 | $84.54 |
| A6456 | Zinc paste impregnated bandage, non-elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | <1% | 38 | $64.46 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 39 | $61.91 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 17 | $44.75 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 502 | $43.90 |
| 84100 | <1% | 16 | $37.26 | |
| 87205 | <1% | 12 | $37.17 | |
| 94760 | <1% | 284 | $35.12 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 62 | $34.66 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 208 | $31.52 |
| 96376 | <1% | 778 | $31.04 | |
| 87186 | <1% | 152 | $30.00 | |
| 87088 | <1% | 119 | $13.78 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 467 | $13.50 |
| 85379 | <1% | 114 | $10.18 | |
| 76830 | Ultrasound, transvaginal | <1% | 66 | $4.10 |
| 86901 | <1% | 69 | $2.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 100 | $1.85 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 55 | $0.00 |
| 85007 | 0% | 14 | $0.00 | |
| 91300 | 0% | 697 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 69 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 16 | $0.00 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 20 | $0.00 |
| 91301 | 0% | 13 | $0.00 | |
| 94761 | 0% | 165 | $0.00 | |
| 87581 | 0% | 56 | $0.00 | |
| 87147 | 0% | 27 | $0.00 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | 0% | 27 | $0.00 |
| 86140 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDEFURIO, ANTHONY (EXECUTIVE VICE PRESIDENT/CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.